Media Center
17
2022y08m
Belief BioMed’s AAV-based Gene Therapy Drug Candidate was Granted Orphan Drug Designation by the FDA
Belief BioMed (BBM, Company) announced today, that its self-developed and manufactured BBM-H901 injection has been granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B. It is the first gene
20
2022y05m
Clinical Trial Results of Belief BioMed's Hemophilia B Gene Therapy Drug Candidate BBM-H901 Published in The Lancet Haematology
The early phase clinical trial results of BBM-H901, the first intravenously injectable hemophilia B gene therapy product developed and tested in Asia, are published in The Lancet Haematology, a top international journal in hematology. https://www.thelance
30
2021y12m
Belief BioMed Completed Dosing of the First Subject in the Registrational Gene Therapy Clinical Trial for Hemophilia B
On December 30th, 2021, Belief BioMed Group（BBM）announced that it has successfully dosed the first subject in the registrational gene therapy clinical trial by intravenous (IV) infusion of BBM-H901, an adeno-associated virus (AAV) vector expressing facto…
10
2021y08m
Belief Biomed’s Gene Therapy for Hemophilia B Receives NMPA IND Approval: First Intravenous Infusion Gene Therapy for Rare Disease in China
On August 10th, 2021，Belief Biomed announced that China’s National Medical Products Administration (NMPA) has cleared the IND (Investigational New Drug) application for Belief Biomed’s BBM-H901. This marks the first IND approval for Intravenous （i.v.）…
28
2020y10m
Belief BioMed announced the opening of new development & manufacturing center in Minhang Shanghai
On Oct 18th，2020, Belief BioMed held the opening ceremony of the new development & manufacturing center at ECUST Science and Technology Park in Minhang Shanghai. More than 80 guests attended the event, including leaders from Minhang District and Meilo
28
2019y10m
Belief BioMed seized the new developing opportunity of Lin-gang and signed a contract to construct the key project in Lin-gang Biotechnology Industrial Park
On October 18th, 2019, in the signing ceremony “Promoting biomedical industry key projects of Lin-gang Special Area in China (Shanghai) Pilot Free Trade Zone” and the opening ceremony of Lin-gang Special Area Life Science Park, Belief BioMed became one o…
27
2019y01m
Belief BioMed Invests Over 100 million RMB to Construct a State-Of-The-Art Gene Therapy Manufacturing plant in Minhang Shanghai.
With the rapid development of the company in 2018, Belief BioMed plans to build a new GMP manufacturing plant to meet the expanding demand in the future. The new plant covers an area of 5000m2 and has multiple production facilities capable of producing ad
Belief BioMed Investor Relations
Email: IR_BBM@beliefbiomed.com